ELGAN Pharma Secures $2.5 Million Grant to Advance Life-Saving Treatment for Preterm Infants with Intestinal Malabsorption!

Elgan Pharma is proud to announce that it has received a substantial grant of €2.36 million ($2.5 million) from the European Innovation Council (EIC) to help support the Phase III clinical trial of their revolutionary ELGN-GI treatment.

This innovative oral formulation is designed to help combat intestinal malabsorption in preterm infants, a long-standing major challenge in neonatal care. The grant is a recognition of the company’s commitment to delivering treatments that have the potential to make a significant impact on the well being of those affected.

We are proud and excited to have been awarded the EIC grant, which is a testament to the importance of making medications available to treat intestinal malabsorption in premature infants. Feeding intolerance is a common symptom of intestinal malabsorption in preterm infants, and carries an increased risk of life-threatening complications.

ELGN-GI has demonstrated significant promise in clinical trials, leading to improved maturation of the GI tract and reduced risk of complications due to prematurity. We are confident that ELGN-GI has the potential to improve care for preterm infants around the world, allowing for better outcomes and improved wellbeing.

To further this goal, we are launching a confirmatory Phase III trial, as well as a Phase II trial in special neonatal populations.

The European Innovation Council (EIC) is a groundbreaking program that seeks out, develops and propels the world’s most cutting-edge innovations. By providing generous grants and support, this program helps burgeoning startups in a variety of fields, from science and technology to different industry sectors, realise their creative potential and become world-leading technological forces.


ELGN-GI is a revolutionary new treatment that can help babies with insulin needs transition more quickly to full enteral nutrition. By delivering a specially formulated recombinant human insulin designed for infant needs orally, it reduces the need for more invasive intravenous feeding – and its associated risks. ELGN-GI also has the additional benefit of helping to improve gastrointestinal development for healthier, happier babies.

About Gastrointestinal Complications in Preterm Infants

Preterm births can be incredibly challenging, coming with increased risks of infant mortality and morbidity. A major challenge faced with preemies is malabsorption of enteral nutrition due to an immature gut.

This can result in life-threatening complications such as gut atrophy and necrotizing enterocolitis (NEC). To date, there is still no viable solution to this medical need and current management is through parenteral nutrition (PN).

Although such intravenous nutrition bypasses the gastrointestinal tract, it still puts the infant at risk of infection and sepsis, liver damage, gut atrophy, and poorer developmental outcomes. Therefore, addressing this challenge continues to remain an unmet medical necessity.

About Elgan Pharma

Elgan Pharma is on a mission to change the lives of preterm babies worldwide. The clinical stage biotechnology company is dedicated to developing safe and tailored therapies to address medical or developmental complications that these babies usually face.

Currently, Elgan Pharma is pioneering two innovative programs: ELGN-GI to support preterm infants’ intestinal malabsorption, and ELGN-EYE to prevent retinopathy of prematurity – the most frequent cause of childhood blindness in the world.

Leave a Comment